P
Prakash S. Masurekar
Researcher at Merck & Co.
Publications - 39
Citations - 743
Prakash S. Masurekar is an academic researcher from Merck & Co.. The author has contributed to research in topics: Fermentation & Cholesterol oxidase. The author has an hindex of 13, co-authored 39 publications receiving 684 citations. Previous affiliations of Prakash S. Masurekar include Eastman Kodak Company.
Papers
More filters
Journal ArticleDOI
Discovery and development of first in class antifungal caspofungin (CANCIDAS®)—A case study
James M. Balkovec,David L. Hughes,Prakash S. Masurekar,Carole A. Sable,Robert E. Schwartz,Sheo B. Singh +5 more
TL;DR: This paper describes a fifteen year journey from concept to clinical discovery and development of the first in class caspofungin acetate (CANCIDAS®) a parenteral antifungal agent.
Journal ArticleDOI
Reclassification of a pneumocandin-producing anamorph, Glarea lozoyensis gen. et sp. nov., previously identified as Zalerion arboricola
TL;DR: The genus Zalerion is artificial; its species bear no phylogenetic relation among themselves, and a new anamorph genus and species is proposed, Glarea lozoyensis, to accommodate ATCC 20868.
Journal ArticleDOI
Pneumocandins from Zalerion arboricola. II. Modification of product spectrum by mutation and medium manipulation.
TL;DR: Subsequent development of another series of media containing Pharmamedia as a nitrogen source resulted in increase in production by 10- approximately 20-fold and substantial improvement in the production of A0 as well as discovery and/or facile production of 7 other related compounds.
Journal ArticleDOI
Isolation, structure, and antibacterial activity of philipimycin, a thiazolyl peptide discovered from Actinoplanes philippinensis MA7347.
Chaowei Zhang,James L. Occi,Prakash S. Masurekar,John F. Barrett,Deborah L. Zink,Scott K. Smith,Russell Onishi,Sookhee Ha,Oscar Salazar,Olga Genilloud,Angela Basilio,Francisca Vicente,Charles Gill,Emily Hickey,Karen Dorso,Mary Motyl,Sheo B. Singh +16 more
TL;DR: A highly specific assay with a pair of thiazomycin sensitive and resistant strains of Staphylococcus aureus led to the discovery of philipimycin, a new thiazolyl peptide glycoside, which showed strong antibacterial activities against gram-positive bacteria including MRSA.
Journal ArticleDOI
Thiazomycins, thiazolyl peptide antibiotics from Amycolatopsis fastidiosa.
Chaowei Zhang,Kithsiri Herath,Hiranthi Jayasuriya,John G. Ondeyka,Deborah L. Zink,James L. Occi,Gwyneth Birdsall,Jayashree Venugopal,Misti Ushio,Bruce Burgess,Prakash S. Masurekar,John F. Barrett,Sheo B. Singh +12 more
TL;DR: The discovery of the truncated compounds revealed the minimal structural requirements for activity and suggested probable biosynthetic pathways for more advanced compounds.